334 related articles for article (PubMed ID: 33868234)
1. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia.
Wang Z; Chen J; Wang M; Zhang L; Yu L
Front Immunol; 2021; 12():618710. PubMed ID: 33868234
[TBL] [Abstract][Full Text] [Related]
2. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.
Kikushige Y
Cancer Sci; 2021 Sep; 112(9):3419-3426. PubMed ID: 34159709
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.
Wu Z; Ou J; Liu N; Wang Z; Chen J; Cai Z; Liu X; Yu X; Dai M; Zhou H
Cancer Med; 2023 Apr; 12(7):8956-8969. PubMed ID: 36545697
[TBL] [Abstract][Full Text] [Related]
4. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
5. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
[TBL] [Abstract][Full Text] [Related]
6. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
8. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.
Kikushige Y; Miyamoto T; Yuda J; Jabbarzadeh-Tabrizi S; Shima T; Takayanagi S; Niiro H; Yurino A; Miyawaki K; Takenaka K; Iwasaki H; Akashi K
Cell Stem Cell; 2015 Sep; 17(3):341-52. PubMed ID: 26279267
[TBL] [Abstract][Full Text] [Related]
9. [A TIM-3/galectin-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemia progression].
Kikushige Y
Rinsho Ketsueki; 2016 Apr; 57(4):412-6. PubMed ID: 27169443
[TBL] [Abstract][Full Text] [Related]
10. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
11. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages.
Gao L; Yu S; Zhang X
Cell Biochem Biophys; 2014 Sep; 70(1):273-7. PubMed ID: 24639110
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
Wang J; Yang L; Dao FT; Wang YZ; Chang Y; Xu N; Chen WM; Jiang Q; Jiang H; Liu YR; Qin YZ
Leuk Lymphoma; 2022 Jan; 63(1):152-161. PubMed ID: 34405769
[TBL] [Abstract][Full Text] [Related]
13. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
14. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
15. [TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in human acute myeloid leukemia].
Sakoda T; Kikushige Y
Rinsho Ketsueki; 2023; 64(6):547-552. PubMed ID: 37407480
[TBL] [Abstract][Full Text] [Related]
16. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
Marchand T; Pinho S
Front Immunol; 2021; 12():775128. PubMed ID: 34721441
[TBL] [Abstract][Full Text] [Related]
17. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.
Gonçalves Silva I; Gibbs BF; Bardelli M; Varani L; Sumbayev VV
Oncotarget; 2015 Oct; 6(32):33823-33. PubMed ID: 26413815
[TBL] [Abstract][Full Text] [Related]
18. The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.
Bruno S; Mancini M; De Santis S; Monaldi C; Cavo M; Soverini S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202238
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
Chajuwan T; Kansuwan P; Kobbuaklee S; Chanswangphuwana C
Leuk Lymphoma; 2022 Feb; 63(2):450-456. PubMed ID: 34585994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
